This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A major hurdle to the efficacy of adoptive cell therapy and chimeric antigen receptors T-cell therapy is the choice of antigen(s) to target. An article in this issue addresses this by capitalizing on the synergistic effect of pathogen-based immunotherapy and adoptive cell therapy that results in epitope/antigen spreading and enhancement of the endogenous T-cell response against antigens not originally targeted.
See article by Xin et al., p. 7
Footnotes
Cancer Immunol Res 2020;8:2
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2020
Volume 8, Issue 1
Volume 8, Issue 1
Tumor Antigen Heterogeneity: The “Elephant in the Room” of Adoptive T-cell Therapy for Solid Tumors
Jump to section
Advertisement